That time APOE met Alpha Syn

Related Articles:

• Similarities between Alzheimer's and Parkinson's February 13, 2020 Recently, two research groups independently published journal articles suggesting that a genetic variation associated with Alzheimer's might also have an important influence in Parkinson's and related conditions. The scientists found that a protein called Apolipoprotein E (or ApoE) can affect the severity of the toxic accumulation of alpha synuclein protein in the Parkinsonian brain – a well-known trait of Parkinson's .…
• Denali Announce Positive LRRK2 Trial Results with Advance to Phase 1b Trial August 16, 2018 Denali Therapeutics has announced positive clinical results from their LRRK2 inhibitor programme and their advance to a Phase 1b trial in Parkinson’s patients with and without a genetic LRRK2 mutation. Genetic mutations (or variants) within the LRRK2 gene are recognised as being some of the most common with regards to increasing ones risk of developing Parkinson’s. But despite being one…
• Denali Announce Positive LRRK2 Trial Results with Advance to Phase 1b Trial August 16, 2018 Denali Therapeutics has announced positive clinical results from their LRRK2 inhibitor programme and their advance to a Phase 1b trial in Parkinson’s patients with and without a genetic LRRK2 mutation. Genetic mutations (or variants) within the LRRK2 gene are recognised as being some of the most common with regards to increasing ones risk of developing Parkinson’s. But despite being one…
• A Greater Role for the Parkinson's GBA Gene Protein? June 22, 2020 There is a great deal of variability in symptoms, severity and age of onset between each person affected by Parkinson's. Tremendous research efforts are currently focused on improving our understanding of these differences and how they arise. Better knowledge of them could not only provide insights into the underlying biology of Parkinson's but could also help us understand how best…
• Repurposed cancer drug shows promise for Parkinson’s December 5, 2018 Researchers at the Oxford Parkinson’s Disease Centre, UK, have repurposed an experimental cancer drug – called tasquinimod – as a potential treatment for Parkinson’s. The study – funded by Parkinson’s UK and published in science journal ‘Cell Stem Cell’ – has been tested on a total of 10 patients so far. As part of the research, the study grew brain…
• Another Ambroxol-like Drug for Treating Parkinson's? October 17, 2019 Tiny variations in DNA are associated with approximately 20% of Parkinson's cases. One of the most common genetic risk factor occurs in a region of DNA called the GBA gene. This sequence of DNA provides the instructions for producing an enzyme - called GCase - which cells use to break down and dispose of waste and unwanted products in cells.…
• Genome Editing in Neurosciences July 18, 2019 Genome Editing in Neurosciences Book. 2017 Authors: Jaenisch R, Zhang F, Gage F Abstract Genes linked to major neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Huntington’s diseases, were first identified over 15 years ago, but neither a full molecular explanation for the cell loss seen in human patients nor a curative therapy has yet been achieved for any of these diseases. In…
• 3P - Post Doc Seminar - 30 July July 13, 2020 Join the next 3P Seminar live on Thursday 30 July at 5.00pm BST (12.00 EST) as Benoît Vanderperre, Research Associate at Edward Fon’s lab (McGill University) and William Hancock-Cerutti, MD-PhD candidate at Pietro De Camilli’s lab (Yale University), present on “The Cell Biology of Parkinson’s disease”. Benoît’s presentation will focus on: Genetic modifiers of alpha-synuclein uptake (“A Genome-Wide CRISPR Screen Identifies Genetic…
• APOE Gene Variants Alter Alpha-synuclein Dynamics, Could Affect Dementia Occurrence in Parkinson’s, Study Suggests February 11, 2020 Genetic variations in the gene apolipoprotein E (APOE) alter the dynamics of alpha-synuclein protein buildup in the brains of mice with Parkinson’s disease (PD), according to a new study. This suggests suggests that alterations in APOE could affect the occurrence of dementia in humans with the neurodegenerative disease, the researchers said. Titled “APOE genotype regulates pathology and disease progression in…
• It’s been 50 years since 6/6/66, Life, so can I have a word? June 6, 2016 Writing Smiles and Tears   You’ve stuck by me for 50 years now Life. And you’ve given me a lot. A healthy and playful youth, two degrees, a couple of foreign forays in London and Tokyo, a career, the lot. Thank you, Life. You’ve given me 2600 weeks, the last 1200 of which the ‘we’ has embraced the ‘me’. Life […]…
• It’s in the genes August 20, 2018   For many years Parkinson’s was thought to be an idiopathic condition – something that does not have a defined cause. This view changed in the 1990’s when it was discovered that certain genes were, after all, associated with Parkinson’s. Mutations were identified in the LRRK2, PARK7, PINK1, PRKN, or SNCA genes or by alterations in genes that have not…
• Mutations in Genes Other Than GBA May Collectively Raise Parkinson’s Risk and Severity, Study Suggests August 26, 2019 Mutations in the SNCA and CTSB genes — among the many known to increase the likelihood of Parkinson’s disease — also contribute to the risk associated with mutations in the GBA gene, one of this disease’s most common and significant genetic risk factors, a study shows. Its results further suggest an interaction between the CTSB and GBA genes, and that raising the levels of…
• LRRK2 - Parkinson's, Leprosy, and Crohn’s October 3, 2019 Researchers at the University of Ottawa have announced a new discovery associated with a genetic form of Parkinson's. Individuals with a genetic variation in a region of DNA for leucine-rich repeat kinase-2 (or simply LRRK2) have a higher risk of developing Parkinson's, as well as leprosy, and Crohn’s disease. Why this is the case has been a mystery for a…
• 3D Structure of Alpha-Synuclein Challenges Previous Theory of Parkinson’s July 11, 2018 Researchers have analyzed the three-dimensional toxic form of the protein alpha-synuclein, which is directly involved in Parkinson’s disease. The findings are now challenging previous knowledge investigators had of this disease. Parkinson’s disease is a progressive neurodegenrative disorder that belongs to the class of synucleopathies. In these type of diseases, a protein called alpha-synuclein is abnormally high. When this protein clumps…
• E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease. June 27, 2019 E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease. PLoS One. 2019;14(6):e0218261 Authors: Sakai R, Suzuki M, Ueyama M, Takeuchi T, Minakawa EN, Hayakawa H, Baba K, Mochizuki H, Nagai Y Abstract Parkinson's disease (PD) is one of the most common neurodegenerative diseases, which is characterized by progressive…
• From Genetics to Clinic November 1, 2018 Studying the rare to understand the common and treat all has been a fruitful strategy in the hunt for disease modifying treatments. Most forms of Parkinson’s (PD) are caused by the complex interplay of genetic and environmental factors, and in only 5-10% of cases can a single gene be identified. Nonetheless, 1 in 5 people with Parkinson’s report having an…
• From Genetics to Clinic November 1, 2018 Studying the rare to understand the common and treat all has been a fruitful strategy in the hunt for disease modifying treatments. Most forms of Parkinson’s (PD) are caused by the complex interplay of genetic and environmental factors, and in only 5-10% of cases can a single gene be identified. Nonetheless, 1 in 5 people with Parkinson’s report having an…
• What’s Hot in PD?: What Are GBA Mutations and How Can Having One Potentially Affect My Parkinson’s Disease? July 6, 2017 Each year, scientists take us a little closer to understanding the genetics of Parkinson’s disease (PD). Perhaps the most interesting and perplexing finding so far has been that only 10 to 15 percent of cases are associated with a change in DNA (this is known as a genetic mutation). Because of this, it is thought that Parkinson’s has both genetic…
• Keeping Pace of LRRK2 and GCase December 10, 2019 There are a number of genetic variations that can increase one's risk of developing Parkinson's. Two of the most common genetic variations or mutations occur in regions of human DNA known as the 'LRRK2' gene and the 'GBA' gene (a gene being a functional section of DNA). These mutations usually occur independent of each other, and they are very rare…
• Loss of Function in Key Genes Doesn’t Change Parkinson’s Risk, Study Finds August 3, 2018 Loss or inactivation of a single gene copy of LRRK1 or LRRK2 — LRRK mutations being a common genetic cause of Parkinson’s disease — neither increases the risk nor protects against the disease, a new study showed. These findings also support the use of kinase inhibitors targeting mutant LRRK2 as a therapeutic option for the disease. The study, “Frequency of Loss…